中文摘要：

微小染色体维持蛋白2（minichromosome maintenance protein 2,MCM2）是真核细胞DNA复制启动的许可因子。其mRNA水平在细胞周期中是呈周期性变化的,一些细胞周期相关因子通过调控MCM2可干预DNA的复制。其只在增殖细胞周期中表达,被视为特异性增殖相关因子,能够用于检测具有增生潜能的细胞和较好地区分正常组织、不典型增生及肿瘤组织。其异常表达反映了具有癌变潜能的细胞被锁定在细胞周期中不断地进行异常复制、增殖,其标记指数越高预示肿瘤恶性程度越高,预后越差,故MCM2是研究肿瘤细胞能动性及判定肿瘤预后的有效指标。MCM2与宫颈病变的关系经过了多年的研究,其作为肿瘤标志物加入宫颈病变的筛查提高了宫颈癌前病变的检出率并有助于宫颈癌预后的判定,而MCM2的抗体或抑制剂有望成为宫颈癌治疗的新靶点。

英文摘要：

Minichromosome maintenance protein 2（MCM2） is a licensing factor in the initiation of eukaryotic DNA replication.The mRNA level of MCM2 in the cell cycle is a cyclical change.A number of cell cycle related factors intervene with the cell DNA replication through the regulation of MCM2.It is regarded as a specific factor related to proliferation for its expression only in the proliferating cell cycle.MCM2 antibody is used to test the existing of poten tial proliferating cells and better distinguish normal tissues,atypical hyperplasia and tumors.Its abnormal expression re flects that these potentially cancerous cells are locked in the cell cycle and continuously abnormal replication and proliferation.The higher its labellingindex,the higher malignant degree of tumor,the worse prognosis.MCM2 is an ef fective indicator in researching on tumor cell motility and judging tumor prognosis.since the relationship between MCM2 with cervical lesions has been studied for many years,the application of MCM2 as a tumour marker for cervical screening improves the checkout rate of the cervical precancerous lesions and is conduced to evaluate prognosis about cervical carcinomas.Its antibody or inhibitor is hopeful as a new target for cervical carcinoma treatment.